$CLBT

Stock Market Today, Aug. 13: Cellebrite Shares Plummet 29% After Missing Earnings, Cutting 2026 Revenue Guidance

Cellebrite DI (CLBT) shares fell 29.18% to $10.80 after the company missed quarterly earnings and cut full-year revenue guidance, including Q3 growth guidance of 19.5% and 2026 growth of 15%. The article also notes a CEO transition to Shiven Ramji and higher trading volume versus average.

Original reporting
Published Aug 13, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stock Market Today, Aug. 13: Cellebrite Shares Plummet 29% After Missing Earnings, Cutting 2026 Revenue Guidance — source image
Decision brief

The 30-second read

$CLBTBearishHigh
01

Why it matters

The key new information is the combination of an earnings miss and a reduction in revenue growth guidance for both the near term (Q3) and longer term (2026), driving a large drawdown and high-volume trading.

02

Market read

This is a direct repricing event for CLBT, with traders likely focusing on whether the new CEO can reverse execution and margin trends after the guidance reset.

03

What to watch

New CEO Shiven Ramji taking over could change execution; traders may be over-weighting the guidance cut versus early product momentum and AI monetization progress.

Relevance 9/10Novelty 9/10Timing: same-day after-hours/close reaction to earnings and guidance cut (Aug. 13)

Background

CLBT is a digital forensics and investigative intelligence software provider; it IPO’d in 2020 and has been a growth stock since.

Company-level read

Ticker impact

$CLBTBearishHigh confidence
Context

Cellebrite shares fell 29.18% after the company missed earnings and cut full-year revenue guidance, including 2026 growth.

Expected impact

Bearish near-term bias, with potential for further volatility as investors reprice growth and margin expectations.

Evidence & confidence

The article cites a quarterly earnings miss and explicit guidance reductions for Q3 and 2026, coinciding with a large single-day selloff and heavy volume.

Market effects

Digital forensics and investigative intelligence software investors may demand faster growth and clearer margin trajectory after CLBT’s guidance reset.

Limited direct regional spillover; move is company-specific within US-listed software.

Modest global relevance, mainly affecting sentiment toward law-enforcement/enterprise investigation software providers.

Counterpoint

The article notes Guardian, Pathfinder, and Corellium products more than doubled sales and Genesis AI monetization began in Q2, which could offset the guidance cut if margins improve.

Key entities

  • Cellebrite DI

    Digital forensics and investigative intelligence software provider whose shares dropped 29% after missing earnings and cutting revenue guidance.

  • Shiven Ramji

    Incoming CEO, previously President of Technology and Products at Cellebrite and prior ID business president at Okta.

Related articles

$CLBTHighAI 9/10

Why is Cellebrite stock plunging today?

Cellebrite (CLBT) shares fell about 28% in pre-open after Q2 2026 results and a leadership change. EPS was $0.11 vs $0.07 consensus, but revenue missed at $131.14M vs $131.87M. Guidance was cut: FY 2026 ARR to $550M-$560M and revenue to $550M-$560M, below $568M consensus. CEO change and a Form 144 insider sale added pressure.

$GSKMed

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?

GSK plc reported Q2 results on July 28. Total turnover was £8.4bn, up 5% CER. Core operating profit rose 7% CER to £2.80bn and Core EPS increased 9% CER to 50.5p, driven by Specialty Medicines and Vaccines. Total operating profit fell 75% CER due to a £1.3bn non-cash impairment after discontinuing camlipixant. GSK also outlined a 2026 Phase III acceleration plan and a £1.9bn annual cost-savings restructuring program.